Basepoint Wealth’s Catalyst Pharmaceutical CPRX Stock Holding History

Basepoint Wealth’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.5K	Hold	787	–	–	0.01%	334
2025 Q4	$18.4K	Buy	+787	New	+$17.5K	0.01%	335

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Basepoint Wealth's CPRX Position: Q1 2026 in Review

Basepoint Wealth held its Catalyst Pharmaceutical (CPRX) position steady in Q1 2026 at 787 shares worth $19.5K. The position accounts for 0.01% of the portfolio, ranked #334.

Basepoint Wealth first reported a position in CPRX in Q4 2025 and has held it in 2 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Basepoint Wealth held 787 shares of Catalyst Pharmaceutical worth $19.5K as of Q1 2026.
Basepoint Wealth left its Catalyst Pharmaceutical share count unchanged in Q1 2026.
Catalyst Pharmaceutical made up 0.01% of Basepoint Wealth's portfolio in Q1 2026, its #334 holding.
Basepoint Wealth first reported a position in Catalyst Pharmaceutical in Q4 2025 and has held it in 2 quarters since.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Basepoint Wealth's 13F filing for Q1 2026, filed 7 May 2026.